Ipilimumab-Induced Neutropenia in Melanoma

Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ban-Hoefen, Makiko, Burack, Richard, Sievert, Lynn, Sahasrabudhe, Deepak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984314/
https://www.ncbi.nlm.nih.gov/pubmed/27570779
http://dx.doi.org/10.1177/2324709616661835
_version_ 1782447955648708608
author Ban-Hoefen, Makiko
Burack, Richard
Sievert, Lynn
Sahasrabudhe, Deepak
author_facet Ban-Hoefen, Makiko
Burack, Richard
Sievert, Lynn
Sahasrabudhe, Deepak
author_sort Ban-Hoefen, Makiko
collection PubMed
description Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies.
format Online
Article
Text
id pubmed-4984314
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-49843142016-08-26 Ipilimumab-Induced Neutropenia in Melanoma Ban-Hoefen, Makiko Burack, Richard Sievert, Lynn Sahasrabudhe, Deepak J Investig Med High Impact Case Rep Case Report Ipilimumab is a human monoclonal IgG1 antibody against CTLA-4 that has been shown to prolong the overall survival of advanced melanoma. The most common adverse events associated with ipilimumab are immune-related. Severe hematological toxicity is rare. We report a case of severe neutropenia following ipilimumab therapy that fully resolved after the administration of prednisone, cyclosporine, and anti-thymocyte globulin therapies. SAGE Publications 2016-08-09 /pmc/articles/PMC4984314/ /pubmed/27570779 http://dx.doi.org/10.1177/2324709616661835 Text en © 2016 American Federation for Medical Research http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution 3.0 License (http://www.creativecommons.org/licenses/by/3.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Ban-Hoefen, Makiko
Burack, Richard
Sievert, Lynn
Sahasrabudhe, Deepak
Ipilimumab-Induced Neutropenia in Melanoma
title Ipilimumab-Induced Neutropenia in Melanoma
title_full Ipilimumab-Induced Neutropenia in Melanoma
title_fullStr Ipilimumab-Induced Neutropenia in Melanoma
title_full_unstemmed Ipilimumab-Induced Neutropenia in Melanoma
title_short Ipilimumab-Induced Neutropenia in Melanoma
title_sort ipilimumab-induced neutropenia in melanoma
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984314/
https://www.ncbi.nlm.nih.gov/pubmed/27570779
http://dx.doi.org/10.1177/2324709616661835
work_keys_str_mv AT banhoefenmakiko ipilimumabinducedneutropeniainmelanoma
AT burackrichard ipilimumabinducedneutropeniainmelanoma
AT sievertlynn ipilimumabinducedneutropeniainmelanoma
AT sahasrabudhedeepak ipilimumabinducedneutropeniainmelanoma

Ejemplares similares